XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Share-Based Compensation
 9 Months Ended
Nov. 03, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation SHARE-BASED COMPENSATION
For the thirty-nine weeks ended November 3, 2018 and October 28, 2017, share-based compensation expense was $15.5 million and $14.7 million, respectively. As of November 3, 2018, approximately 7.0 million shares remain available for future grants of equity awards under our Amended and Restated 2012 Omnibus Stock and Incentive Plan, which was amended and restated effective June 22, 2017.
Restricted Stock Awards
Restricted stock awards vest in equal annual installments over a three-year period from the date of grant.
Restricted stock award activity for the thirty-nine weeks ended November 3, 2018 was as follows:

Number of
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested, beginning of period
2,328,259

 
$
13.08

Granted
1,944,280

 
9.68

Vested
(1,047,063
)
 
13.00

Forfeited
(259,668
)
 
11.85

Unvested, end of period
2,965,808

 
10.99


Performance-based Restricted Stock Units
For the thirty-nine weeks ended November 3, 2018, we granted performance-based restricted stock units (“PSUs”), contingent upon the achievement of Company-specific performance goals during the three fiscal years 2018-2020. Any units earned as a result of the achievement of this goal will vest 100% three years from the date of grant and will be settled in shares of our common stock.
Performance-based restricted stock unit activity for the thirty-nine weeks ended November 3, 2018 was as follows:
 
Number of Units/
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested, beginning of period
690,950

 
$
13.65

Granted
725,300

 
9.87

Vested
(190,777
)
 
13.08

Forfeited
(88,188
)
 
13.11

Unvested, end of period
1,137,285

 
11.40


 
Stock Option Awards
For the thirty-nine weeks ended November 3, 2018 and October 28, 2017, we did not grant any stock options.
Stock option activity for the thirty-nine weeks ended November 3, 2018 was as follows:
 
Number of
Options
 
Weighted
 Average
Exercise Price
Outstanding, beginning of period
368,745

 
$
12.36

Granted
—

 
—

Exercised
(21,200
)
 
4.46

Forfeited or expired
(112,268
)
 
13.39

Outstanding and exercisable, end of period
235,277

 
12.58